As a pivotal industry event, the exhibition brought together over 5,000 Chinese pharmaceutical enterprises and finished drug manufacturers, solidifying API China's role as a leader in the global biopharma sector and a catalyst for next-generation innovation. API China 2025 highlighted the pharmaceutical industry's trajectory toward sustained growth and innovation.
The 93rd API China, held from November 12 to 14, 2025, at the Chongqing International Expo Center (CQEXPO), marked a significant milestone as China’s first-of-its-kind and longest-running pharmaceutical ingredients exhibition. Renowned as Asia’s premier pharma and healthcare trade show, API China serves as a vital platform connecting China’s pharmaceutical innovations with global outlets.
Co-located with Pharmex, ChinaPharm, and BioPh China, the 93rd API China formed a comprehensive industry chain exhibition cluster, showcasing policy trends, technological advancements, and trends dialogues.
API China 2025 emphasized its role as a hub for international collaboration, strengthening connections between domestic and global stakeholders in the pharmaceutical raw materials and bioprocessing sectors. The three-day trade fair, covering 70,000 square meters, hosted over 1,200 exhibitors and attracted nearly 30,000 industry professionals visitors from 30+ countries. Held biannually, the event serves as a key platform for showcasing innovations, fostering collaborations, and driving growth in the pharmaceutical and biopharmaceutical sectors.
This year’s theme, “China's Domestic Pharmaceutical Loop Platform, Origin of the Global Pharmaceutical Supply Chain,” underscored the event’s commitment to shaping the future of the global pharmaceutical industry. The exhibition showcased the industry's collaborative efforts to drive progress in healthcare, drug development, and pharmaceutical manufacturing. As part of its prime responsibility in shaping the future of global pharmaceuticals, the exhibition showcased policy trends, industry developments, and opportunities for product display, technological exchange, and business collaboration, demonstrating industry innovation.
Organized by Reed Sinopharm Exhibitions (RSE), the event continues to strengthen international collaboration and advance the future of pharmaceutical innovation and sustainable healthcare solutions. The 2025 edition united global innovators and leaders in the pharmaceutical and healthcare industries, with a focus on advancements in active pharmaceutical ingredients, fine chemicals, excipients, drug formulations, and biotechnology. The event provided a dynamic platform for networking, knowledge exchange, and exploring new business opportunities within China’s rapidly expanding healthcare market.
With a heritage spanning over four decades, API China remains a gateway to China’s fast-evolving pharmaceutical and biopharmaceutical sector. The forum’s primary mission is to support innovation across the entire pharmaceutical value chain, encompassing products and technologies for every stage of the pharmaceutical process, from R&D to production.
Reaffirming China’s Legacy as Global Leader in Active Pharmaceutical Ingredient (API):
Driven by rising healthcare needs, an increase in infectious diseases, and the exponential pharmaceutical production, the China Active Pharmaceutical Ingredient (API) Market is experiencing significant expansion. Government support for innovation and rigorous standards have created a favorable environment for both domestic and international stakeholders. Advanced technologies and strategic partnerships are reshaping the industry, making it a key investment area in the Asia-Pacific region.
China, accounting for approximately 20% of global active pharmaceutical ingredient (API) production, plays a pivotal role in the global pharmaceutical supply chain, exporting its products to 180 countries. China's competitive edge in the global pharmaceutical industry stems from production costs that are 35-40% lower than global averages and advanced quality control systems.
Leading as a cornerstone of the global pharma industry, China’s pharma market forecasts indicate robust growth, with the API manufacturing sector projected to expand from USD 15.9 billion in 2025 to USD 23.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.86%. Therapeutic infusions, such as anti-tumor and immunomodulatory products, are growing at over 15%, driven by precision medicine advancements.
Furthermore, domestic manufacturers benefit from cost advantages, advanced technology, and government incentives, enabling them to compete effectively both locally and globally. Market consolidation through mergers and acquisitions is enhancing R&D capabilities and production capacity, while domestic players are focusing on quality improvements and leveraging government support to maintain their competitive edge.
Meanwhile, continued technological advancements, including synthetic chemistry, process optimization, and biotechnological approaches, are enhancing API quality, cost efficiency, and scalability. Regional dynamics in the API market reflect diverse technological adoption and industrial demand. Continuous manufacturing and automation are boosting scalability and adherence to global standards, while sustainable practices are reducing environmental impact and ensuring regulatory compliance.
Accelerator for Future Innovation and Strategic Partnerships:
API China 2025 facilitated collaboration among biotech innovators, formulation specialists, and health product manufacturers, reinforcing its position as a central hub for the global pharmaceutical industry and a catalyst for future innovation and strategic partnerships. The exhibition covered the entire pharma supply chain, featuring APIs, biopharma innovations, contract manufacturing, chemical intermediates, and pharma packaging solutions.
Some of the Fascinating Elements of API China 2025:
Building on this, the 93rd edition of API China featured over 1,200 enterprises from diverse sectors, including Active Pharmaceutical Ingredients (APIs), intermediates, natural products, pharmaceutical excipients, packaging, equipment, and the biopharmaceutical supply chain. Serving as a comprehensive procurement platform for vendors and buyers, it provided a one-stop solution for sourcing pharma raw materials, and manufacturing resources. A wide array of outsourcing services such as CRO, CDMO, and CMO, offered a detailed overview of the latest advancements and technologies in China's pharmaceutical industry.
Catalyst for Market Growth and Collaboration:
China’s pharmaceutical industry has emerged as a global powerhouse—from R&D and biopharma innovation to large-scale manufacturing and supply chain excellence.
Four parallel exhibitions were held simultaneously to present a comprehensive outlook of China’s Biopharma potential. The key zones namely, the Pharmaceutical API Exhibition, Pharmaceutical Excipients Exhibition, Pharmaceutical Packaging Exhibition and Pharmaceutical Equipment Exhibition, served as dynamic hubs for discovery, networking, and collaboration, creating an integrated network ecosystem where suppliers and buyers could discover the full journey from molecule to medicine.
The exhibition halls were diversified yet interconnected to embrace the integrated ecosystem.
Furthurmore, exclusive theme such as "Full-Chain Collaboration · Green Intelligent Manufacturing · Global Orientation", covered more than ten major segments including pharmaceutical APIs, intermediates, raw materials for biological products, natural extracts and veterinary APIs, so as to achieve full industrial chain coverage.
In a parallel theme “Grand Platform for Chinese Pharmaceutical Inner Cycle, Cradle of Global Pharmaceutical Industrial Chain,” API China connected participants directly with the prominent Chinese pharmaceutical enterprises, offering unmatched opportunities for collaboration, sourcing, and market entry.
Overall, exhibition halls were designed to showcase proprietary bio-manufactured ingredients and advanced synthetic biology platform, delivering high-purity, stable, and sustainable products through an integrated R&D-to-supply chain, ensuring competitive costs and reliable supply chain.
From Molecule to Medicine: A Structured Display of China's API Innovation Landscape
The Asia-Pacific region, particularly China, India, Japan, and South Korea, are leading growth due to industrialization and infrastructure development. However, challenges such as regulatory disparities and supply chain issues remain. Global players are adopting localized strategies to address these challenges, by exploring platforms like API China 2025 which serves as key enablers for market expansion and collaboration to achieve goals. This trend makes API China a highly recommended platform for professionals and organizations across diverse sectors.
Following the trend, the 93rd API China edition went beyond product showcases to highlight active engagement throughout the entire pharmaceutical value chain.
API China 2025 drew a diverse audience, including professionals and organizations engaged in:
The platforms collectively enhanced API China's dominance as the industry's foremost channel for fostering connections and driving growth.
As the flagship event for pharmaceutical raw materials, intermediates, packaging, and equipment, API China 2025 presented the latest technologies, sustainable solutions, and global industry trends.
Also noteworthy were the biopharmaceutical technologies and solutions. Exhibitors showcased advancements in contract manufacturing, research, and development (CROs, CMOs, and CDMOs), reflecting the industry’s growing focus on collaborative innovation. This extensive coverage positioned API China as a prime opportunity for businesses looking to expand their networks and tap into the rapidly growing Chinese pharmaceutical market.
Key Sectors and Product Categories included;
With its unmatched scale and influence, API China 2025 reaffirmed its role as a critical platform for advancing the pharmaceutical and healthcare industries.
The 93rd edition of API China provided a comprehensive showcase of the pharmaceutical industry’s cutting-edge advancements. Attendees connected with key decision-makers, manufacturers, and innovators driving the future of global pharmaceutical and healthcare industries.
Dedicated Business Matching Activities for Buyers and Suppliers:
API China 2025 provided a comprehensive showcase of the pharmaceutical industry’s cutting-edge advancements. Attendees connected with key decision-makers, manufacturers, and innovators driving the future of global pharmaceutical and healthcare industries.
API China organizes dedicated business matching activities to connect buyers and suppliers with aligned priorities. The business matchmaking forum was designed to support innovation, regulatory alignment, and market access in China and beyond, offering a unique perspective on China's rapidly evolving pharmaceutical industry and an opportunity to discover new opportunities.
Furthurmore, exhibitors and buyers engaged across the supply chain, exploring solutions, building networks, and discovering new opportunities, solidifying API China's status as a trusted platform for fostering business connections.
As an embellishment, the API China is providing year-round online and offline engagements, enabling precise customer matching and unlocking global business opportunities for attendees.
With opportunities to connect, collaborate, and shape the future of healthcare, the exhibition spotlighted end-to-end pharma manufacturing solutions, providing a comprehensive overview of the industry’s supply chain and catered to biotech innovators, formulation experts, and health product manufacturers alike.
Network for Innovative Nutraceuticals, Formulations and Functional Ingredients:
The nutritional infusion market, including amino acids and fat emulsions, is projected to grow at a 12% CAGR, representing over 40% of the total market by 2030. API China is dedicated to creating a reliable, verified, and globally integrated supply network for raw materials and functional ingredients, offering products like amino acids, vitamins, sweeteners, plant extracts, and excipients.
API China emphasizes partnerships with GMP/ISO/DMF-certified manufacturers, supply chain reliability, and innovative ingredient solutions for formulation and development, while providing robust documentation, traceability, and quality compliance support. The platform also invites collaboration with manufacturers, suppliers, traders, and distributors across sectors such as food, beverage, and nutraceuticals to drive innovation and ensure consistent quality and pricing.
The digital healthcare market has seen significant growth, with China playing a key role in pharmaceutical packaging innovation. The global pharmaceutical supply chain is undergoing a significant transformation driven by digital and intelligent innovations, with AI in R&D revolutionizing traditional drug development by addressing critical bottlenecks. These trends were clearly demonstrated at API China's exhibition portfolios. AI is transforming drug development by reducing time and costs while improving success rates. As R&D standard continues to elevate, Chinese enterprises are advancing to become industry leaders through technological upgrades.
Enduring Legacy with Unwavering Commitment to Shape the Future of Healthcare:
API China 2025 reaffirmed its position as a premier platform for the pharmaceutical and chemical industries. With a legacy of decades of excellence, API China remains a cornerstone of the pharmaceutical industry organising the largest sourcing platform for pharmaceutical raw materials, intermediates, packaging, and equipment, while driving collaboration and business growth.
The 93rd API China has played a pivotal role in the Chinese pharmaceutical landscape, establishing itself as a vital platform for global pharmaceutical brands to enter and grow in China. The strong industry wide participation underscored confidence in China's growing pharmaceutical sector where iInnovation and cutting-edge advancements have been the focal point of the pharmaceutical industries.
